Synthesis and pharmacological characterization of chiral pyrrolidinylfuran derivatives: The discovery of new functionally selective muscarinic agonists

Journal of Medicinal Chemistry

Volumn 51, Issue 13, 2008, Pages 3905-3912

  Scapecchi, Serena ^a   Nesi, Marta ^a   Matucci, Rosanna ^a   Bellucci, Cristina ^a   Buccioni, Michela ^b   Dei, Silvia ^a   Guandalini, Luca ^a   Manetti, Dina ^a   Martini, Elisabetta ^a   Marucci, Gabriella ^b   Romanelli, Maria Novella ^a   Teodori, Elisabetta ^a   Cirilli, Roberto ^c  

^a UNIVERSITY OF FLORENCE   (Italy)

^b UNIVERSITY OF CAMERINO   (Italy)

^c ISTITUTO SUPERIORE DI SANITÀ   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

2 (2 FURYL) 1 METHYLPYRROLIDINE; 2 (5 METHYL 2 FURYL) 1 METHYLPYRROLIDINE METHIODIDE; FURAN DERIVATIVE; FURTRETHONIUM; METHYLFURTRETHONIUM; MUSCARINIC AGENT; MUSCARINIC M2 RECEPTOR; MUSCARINIC M2 RECEPTOR AGONIST; PYRROLIDINE DERIVATIVE;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CHIRALITY; CRYSTALLOGRAPHY; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG SYNTHESIS; ENANTIOMER; MALE; NONHUMAN; PROTON NUCLEAR MAGNETIC RESONANCE; RAT; REACTION ANALYSIS; STEREOCHEMISTRY; STRUCTURE ANALYSIS;

ANIMALS; CHO CELLS; CIRCULAR DICHROISM; CRICETINAE; CRICETULUS; CRYSTALLOGRAPHY, X-RAY; FURANS; GUINEA PIGS; HUMANS; LUNG; MALE; MODELS, MOLECULAR; MOLECULAR STRUCTURE; MUSCARINIC AGONISTS; PYRROLES; RABBITS; SPECTROPHOTOMETRY; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 46849102135     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm800145d     Document Type: Article

References (44)

1. Caulfield, M. P. Muscarinic receptors-characterization, coupling and function. Pharmacol. Ther. 1993, 58, 319-379.
2. Chavez-Noriega, L. E.; Crona, J. H.; Washburn, M. S.; Urrutia, A.; Elliott, K. J.; Johnson, E. C. Pharmacological characterization of recombinant human neuronal nicotinic acetylcholine receptors h-alpha-2-beta-2, h-alpha-2-beta-4, h-alpha-3-beta-2, h-alpha-4-beta-2, h-alpha-4-beta-4 and h- alpha-7 expressed in Xenopus oocytes. J. Pharmacol. Exp. Ther. 1997, 280, 346-356.
3. Korczyn, A. D. Muscarinic M1 agonists in the treatment of Alzheimer's disease. Expert Opin. Invest. Drugs 2000, 9, 2259-2267.
4. Eisenach, J. C. Muscarinic-mediated analgesia. Life Sci. 1999, 64, 549-554.
5. Dean, B.; Bymaster, F. P.; Scarr, E. Muscarinic receptors in schizofrenia. Curr. Mol. Med. 2003, 3, 419-426.
6. Bachurin, S. O. Medicinal chemistry approaches for the treatment and prevention of Alzheimer's disease. Med. Res. Rev. 2003, 23, 48-88.
7. Messer, W. S. Cholinergic agonists and the treatment of Alzheimer's disease. Curr. Top. Med. Chem. 2002, 2, 353-358.
8. Gualtieri, F. Cholinergic Receptors and Neurodegenerative Diseases. Receptor Chemistry towards the Third Millennium; Elsevier Science B.V.: Amsterdam, 2000; pp 85-89.
9. Beach, T. G.; Walker, D. G.; Roher, A. E.; Potter, P. E. Anti-amyloid activity of cholinergic agents. Drug Dev. Res 2002, 56, 242-247.
10. Gu, Z.; Zhong, P.; Yan, Z. Activation of muscarinic receptors inhibits beta-amyloid peptide-induced signalingin cortical slices. J. Biol. Chem. 2003, 278, 17546-17556.
11. Hock, C.; Maddalena, A.; Raschig, A.; Muller-Spahn, F.; Eschweiler, G.; Hager, K.; Heuser, I.; Hampel, H.; Muller-Thomsen, T.; Oertel, W.; Wienrich, M.; Signorell, A.; Gonzales-Agosti, C.; Nitsch, R. M. Treatment with the selective muscarinic m1 agonist talsaclidine decreases cerebrospinal fluid levels of A beta 42 in patients with Alzheimer's disease. Amyloid: J. Protein Folding Disord. 2003, 10, 1-6.
12. Fisher, A.; Brandeis, R.; Haring, R.; Bar-Ner, N.; Kliger-Spatz, M.; Natan, N.; Sonego, H.; Marcovitch, I.; Pittel, Z. Impact of muscarinic agonists for succesful therapy of Alzheimer's disease. J. Neural Transm. 2002, 62S, 189-202.
13. Caccamo, A.; Oddo, S.; Billings, I. M.; Green, K. N.; Martinez-Coria, H.; Fisher, A.; LaFerla, F. M. M1 receptors play a central role in modulating AD-like pathology in transgenic mice. Neuron 2006, 49, 671-682.
14. Angeli, P. Pentatomic cyclic agonists and muscarinic receptors: a 20 years review. Farmaco 1995, 50, 565-578.
15. Dei, S.; Bellucci, C.; Buccioni, M.; Ferraroni, M.; Gualtieri, F.; Guandalini, L.; Manetti, D.; Matucci, R.; Romanelli, M. N.; Scapecchi, S.; Teodori, E. Synthesis and cholinergic affinity of diastereomeric and enantiomeric isomers of 1-methyl-2-(2-methyl-1,3-dioxolan-4-yl)pyrrolidine, 1-methyl-2-(2-methyl-13-oxathiolan-5-yl)pyrrolidine and of their iodomethylates. Bioorg. Med. Chem. 2003, 11, 3153-3164.
16. Dei, S.; Angeli, P.; Bellucci, C.; Buccioni, M.; Gualtieri, F.; Marucci, G.; Manetti, D.; Matucci, R.; Romanelli, M. N.; Scapecchi, S.; Teodori, E. Muscarinic subtypes affinity and functional activity profile of 1-methyl-2-(2-methyl-1,3-dioxolan-4-yl)pyrrolidine and 1-methyl-2-(2-methyl-1,3- oxathiolan-5-yl)pyrrolidine derivatives. Biochem. Pharmacol. 2005, 69, 1637-1645.
17. 2 partial agonist. J. Med. Chem. 2006, 49, 1925-1931.
18. Hulme, E. C.; Lu, Z.-L.; Bee, M.; Curtis, C. A. M.; Saldanha, J. The conformational switch in muscarinic acetylcholine receptors. Life Sci. 2001, 68, 2495-2500.
19. Shi, L.; Javitch, J. A. The binding site of aminergic G protein-coupled receptors: the transmembrane segments and second extracellular loop. Annu. Rev. Pharmacol. Toxicol. 2002, 42, 437-467.
20. Pigini, M.; Brasili, L.; Giannella, M.; Gualtieri, F. Molecular requirements of the active sites of the cholinergic receptors. Eur. J. Med. Chem. 1981, 16, 415-419.
21. Ellis, J. R.; Ellis, K. A.; Bartholomeusz, C. F.; Harrison, B. J.; Wesnes, K. A.; Erskine, F. F.; Vitetta, L.; Nathan, P. J. Muscarinic and nicotinic receptors synergistically modulate working memory and attention in human. Int. J. Neuropsychopharmacol. 2006, 9, 175-189.
22. Buccafusco, J. J. The Cholinergic Hypothesis: Past and Present. Cognitive Enhancing Drugs; Birkhauser Verlag: Berlin, Germany, 2004; pp 1-10.
23. Jensen, B. Aspects of the Molecular Structure of Acetylcholine and of Related Compounds; FADL'S Forlag: Copenhagen, Denmark, 1984; p 236.
24. Semple, J. E.; Wang, P. C.; Lysenko, Z.; Joullie, M. M. Total synthesis of (+)-furanomycin and stereoisomers. J. Am. Chem. Soc. 1980, 102, 7505-7510.
25. Kenneth, P.; Crawford, R.; Rashatasakhon, P.; Rose, M. Several convenient methods for the synthesis of 2-amido substituted furans. J. Org. Chem. 2003, 68, 2609-2617.
26. Otazo-Sanchez, E.; Perez-Marin, L.; Estevez-Hernandez, O.; Rojas-Lima, S; Alonso-Chamarro, J. Aroylthioureas: new organic ionophores for heavy-metal ion selective electrodes. J. Chem. Soc., Perkin Trans. 2001, 11, 2211-2218.
27. 13C nuclear magnetic resonance of piperidine nuphar alkaloids. J. Org. Chem. 1977, 42, 2113-2118.
28. Helak, B.; Kersten, E.; Spengler, K.; Tressl, R.; Rewicki, D. Formation of furylpyrrolidines and piperidines on heating L-proline with reducing sugars and furancarboxaldehydes. J. Agric. Food Chem. 1989, 37, 405-410.
29. Guadalini, L.; Norcini, M.; Varani, K.; Pistolozzi, M.; Gotti, C.; Bazzicalupi, C.; Martini, E. D., S.; Manetti, D.; Scapecchi, S.; Teodori, E.; Bertucci, C.; Ghelardini, C.; Romanelli, M. N. Design, synthesis and preliminary pharmacological evaluation of new quinoline derivatives as nicotinic ligands. J. Med. Chem. 2007, 50, 4993-5002.
30. Gassman, P. G.; Hodgson, P. K. G.; Balchunis, R. J. Base-promoted hydrolysis of amides at ambient temperatures. J. Am. Chem. Soc. 1976, 98, 1275-1276.
31. Scapecchi, S.; Marucci, G.; Angeli, P.; Bellucci, C.; Dei, S.; Gualtieri, F.; Manetti, D.; Romanelli, M. N.; Teodori, E. Structure-activity relationships in 2,2-diphenyl-2-ethylthioacetic acid esters: unexpected agonistic activity in a series of muscarinic antagonists. Bioorg. Med. Chem. 2001, 9, 1165-1174.
32. Caulfield, M. P.; Birdsall, N. J. International Union of Pharmacology XVII. Classification of muscarinic acetylcholine receptors. Pharmacol. Rev. 1998, 50, 279-290.
33. Budriesi, R.; Cacciaguerra, S.; Di Toro, R.; Bolognesi, M. L.; Chiarini, A.; Minarini, A.; Rosini, M.; Spampinato, S.; Tumiatti, V.; Melchiorre, C. Analysis of the muscarinic receptor subtype mediating inhibition of the neurogenic contractions in rabbit isolated vas deferens by a series of polymethylene tetra-amines. Br. J. Pharmacol. 2001, 132, 1009-1016.
34. 3H]4-DAMP-binding. Pulm. Pharmacol. 1993, 6, 119-127.
35. Roffel, A. F.; Davis, J. H.; Elzinga, C. R. S.; Wolf, D.; Zaagsma, J.; Kilbinger, H. Characterization of the muscarinic receptor subtype(s) mediating contraction of the guinea-pig lung strip and inhibition of the acetylcholine release in the guinea-pig trachea with the selective muscarinic receptor antagonist tripitamine. Br. J. Pharmacol. 1997, 122, 133-141.
36. Kenakin, T. New concepts in drug discovery: collateral efficacy and permissive antagonism. Nat. Rev. Drug Discovery 2005, 4, 919-927.
37. Kenakin, T. Collateral efficacy in drug discovery: taking advantage of the good (allosteric) nature of 7TM receptors. TiPS 2007, 28, 407-415.
38. Walker, N.; Stuart, D. Acta Cystallogr. A 1983, 39, 158-166.
39. Burla, M. C.; Camalli, M.; Carrozzini, B.; Cascarano, G. L.; Giacovazzo, C.; Polidori, G.; Spagna, R. SIR 2002: the program. J. Appl. Crystallogr. 2003, 36, 1103.
40. Sheldrick, G. M. SHELXL97: Program for Crystal Structure Refinement; Institut für Anorganische Chemie de Universitat Göttingen: Göttingen, Germany, 1998.
41. Dorje, F.; Wess, J.; Lambrecht, G.; Tacke, R.; Mutschler, E.; Brann, M. R. Antagonist binding profiles of five cloned human muscarinic receptor subtypes. Pharmacol Exp. Ther. 1991, 256, 727-733.
42. Bradford, M. M. A rapid and sensitive method for quantitation of microgram quantities of protein, utilizing the principle of protein-dye binding. Anal. Biochem. 1976, 72, 248-254.
43. Munson, P. J.; Rodbard, D. LIGAND: a versatile computerized approach for the characterization of ligand-binding systems. Anal. Biochem. 1980, 107, 220-239.
44. 2 receptors mediating opposite effects on neuromuscular transmission in rabbit vas deferens. Eur. J. Pharmacol. 1988, 151, 205-221.